Brief: Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy
11/05/2026 13:57
May 11 (Reuters) - Inhibrx Biosciences Inc INBX.O: INHIBRX REPORTS INTERIM PHASE 2 DATA FOR INBRX-106 IN FIRST-LINE HNSCC; INITIAL RESULTS DEMONSTRATE POTENTIAL COSTIMULATORY BENEFIT OVER PD-1 MONOTHERAPY INHIBRX BIOSCIENCES INC - INBRX-106 PLUS PEMBROLIZUMAB ACHIEVES 44.0% CONFIRMED ORR VERSUS 21.4% WITH PEMBROLIZUMAB ALONE INHIBRX BIOSCIENCES INC - THREE COMPLETE RADIOGRAPHIC RESPONSES OBSERVED WITH INBRX-106 PLUS PEMBROLIZUMAB INHIBRX BIOSCIENCES INC - UP TO 15-FOLD INCREASE IN SYSTEMIC T-CELL EXPANSION WITH INBRX-106 PLUS PEMBROLIZUMAB Source text: ID:nPn8skHlwa Further company coverage: INBX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibrx Biosciences
See all newsInhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study (updated)
Inhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study
NASDAQ RESUMED AT 08:00 AM
Brief: Inhibrx's Inbrx-106 Nearly Doubles Response Rate And Achieves Interim Median Pfs Of 9.6 Months In Phase 2 Hnscc Study
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:25 AM